Hypoxia augments cytokine (transforming growth factor-beta (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts

Clinical and Experimental Immunology

Volumn 115, Issue 1, 1999, Pages 176-182

  Berse, B ^c   Hunt, J A ^a   Diegel, R J ^a   Morganelli, P ^a   Yeo, K T ^a   Brown, F ^b   Fava, Roy A ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Psychology Service   (United States)

Author keywords

Angiogenesis; Arthritis; Cytokines; Hypoxia VEGF; Transforming growth factor beta

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; INTERLEUKIN 1ALPHA; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTHRITIS; ARTICLE; DERMIS; FIBROBLAST; HUMAN; HUMAN CELL; HYPOXIA; INFLAMMATION; PRIORITY JOURNAL; SYNOVIUM;

ANOXIA; ARTHRITIS; BLOTTING, NORTHERN; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; FIBROBLASTS; HUMANS; INTERLEUKIN-1; LYMPHOKINES; PROTEIN ISOFORMS; RNA, MESSENGER; SYNOVIAL MEMBRANE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0008362637     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00775.x     Document Type: Article

References (26)

1. 1 Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992; 175:1135-8.
2. 2 Koch A. Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998; 41:951-62.
3. 3 Paleolog E, Fava RA. Angiogenesis in rheumatoid arthritis. Spring Sem Immunol 1998 in press.
4. 4 Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability and angiogenesis. Am J Pathol 1995; 146:1029-39.
5. 5 Ferrara N, Davis-Srnyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
6. 6 Fava RA, Olsen NJ, Spencer-Green G et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180:341-6.
7. 7 Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Lee Wong W, Pope RM. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152:4149-56.
8. 8 Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439-42.
9. 9 Detmar M, Yeo K-T, Nagy JA et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995; 105:44-50.
10. 10 Millauer B, Shawer LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367:576-9.
11. 11 Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-5.
12. 12 Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996; 21:397-439.
13. 13 Firestein GS, Zvafiler NJ. Inflammation, 2nd edn. New York: Raven Press, 1992.
14. 14 Allen RE, Blake DR, Nazhat NB, Jones P. Superoxide radical generation by inflamed human synovium after hypoxia. Lancet 1989; 8657:282-3.
15. 15 James MJ, Cleland LG, Rofe AM. Determinants of synovial fluid lactate concentration. J Rheum 1992; 19:1107-10.
16. 16 Yeo KT, Sioussat TM, Faix JD, Senger DR, Yeo TK. Development of time-resolved immunofluorometric assay of vascular permeability factor. Clin Clern 1992; 38:71-75.
17. 17 Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak BF, Claffey K. Hypoxia regulates the expression of vascular permeability factor vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997; 108:263-8.
18. 18 Ballaun C, Weninger W, Uthman A, Weich H, Tschachler E. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol 1995; 104:7-10.
19. 19 Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93:14765-70.
20. 20 Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994; 269:6271-4.
21. 21 Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Letters 1995; 372:83-7.
22. 22 Jackson JR, Minton JAL, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1b. J Rheumatol 1997; 24:1253-9.
23. 23 Fava RA, Olsen N, Keski-Oja J, Moses HL, Pincus T. Active and latent forms of transforming growth factor β activity in synovial effusions. J Exp Med 1989; 169:291-6.
24. 24 Stevens CR, Blake DR, Merry P, Revell PA, Levick JR. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum 1992; 34:1508-13.
25. 25 Connoly DT, Heuvelman DM, Nelson R, Olander JV. Eppley B, Delfino JJ, Siegel NR. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84:1470-8.
26. 26 Berse B, Brown LF, Van De Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol Biol Cell 1992; 3:211-20.